Clopidogrel: study card

Clopidogrel — P2Y12 platelet inhibitor (thienopyridine). Study the mechanism, listed uses and warnings from the US label on one sourced card.

Generic name: Clopidogrel
Class: P2Y12 platelet inhibitor (thienopyridine)
Mechanism: Prodrug; active metabolite irreversibly binds P2Y12 ADP receptors on platelets, inhibiting platelet activation and aggregation.
Used for: Acute coronary syndrome (NSTE-ACS, STEMI); Recent MI, recent stroke; Established peripheral arterial disease
Common side effects: Bleeding; Epistaxis; Hematuria; Bruising
Boxed warning: Reduced antiplatelet effect in patients with two loss-of-function CYP2C19 alleles (poor metabolizers).
Warnings: Avoid omeprazole or esomeprazole; Bleeding risk; Premature discontinuation raises CV risk
Interactions: Omeprazole, esomeprazole (CYP2C19 inhibitors); Opioids; NSAIDs, warfarin, SSRIs, SNRIs

Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.

Drug class families: P2Y12 platelet inhibitors

Read the source label ↗

Label date: 20260909 · For learning, not clinical decisions. US label and brand information; always consult the current source.

Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.

Practice

Pronunciation

Clopidogrel: kloh-PID-oh-grel

Pronunciation is shown for the US English generic name.

Other drugs in the same class

P2Y12 platelet inhibitors: Ticagrelor

Body system

Hematology · 7 Drug cards

Compare with related cards

Ticagrelor

Same class family: P2Y12 platelet inhibitors

Mechanism: Reversibly binds the platelet P2Y12 ADP receptor, preventing signal transduction and platelet activation.

On both cards: Common side effects — Bleeding · Interactions — Opioids

Only on the Ticagrelor card: Used for — Reduction of cardiovascular death, myocardial infarction and stroke risk in adults with acute coronary syndrome or prior myocardial infarction; Reduction of stent thrombosis in adults stented for acute coronary syndrome · Common side effects — Dyspnea · Warnings — Dyspnea; Severe hepatic impairment; False-negative HIT platelet function tests · Interactions — Strong CYP3A inhibitors / inducers; Simvastatin / lovastatin

An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.

Boxed warnings on related cards

Ticagrelor: Significant, sometimes fatal bleeding; avoid with active bleeding or intracranial hemorrhage history.